T-Hawk drug candidate / therapeutic pipeline
Five programs. Three disclosed. All in discovery, and honest about it.
Chronic pain
A non-opioid, mechanism-selective approach to a genetically validated pain target, the largest of T-Hawk's three markets and the reason the convergence thesis matters.
Antimicrobial resistance
Novel antimicrobial scaffolds from venom chemistry, aimed at a global pipeline the WHO describes as critically thin.
Neuropathic pain
Selective peptide modulation of the ion channels underlying neuropathic pain, where small-molecule precision has not been achievable.
Near-term program objective: advance TH-101 through lead identification on the strength of published reference potency data and partner-run patch clamp validation, and file provisional patents covering the initial target activities. See Investor Notes for the funding and milestone picture.